{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-302822","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.007352+00:00","generated_at":"2026-06-21T06:15:12.502652+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cabaletta Bio prices $35M public offering of common stock and pre-funded warrants","bullets":["Offering of 126,815 shares at $5.52/share and pre-funded warrants to purchase 6,213,776 shares at $5.51999 each.","Gross proceeds of ~$35M; net proceeds ~$32.5M after underwriting discounts and expenses.","Oversubscribed offering with participation from Venrock, Adage Capital, Cormorant, and others.","Net proceeds to fund CABA-201 preclinical and IND, and ongoing DSG3-CAART and MuSK-CAART trials.","Closing expected December 12, 2022; Cowen and Evercore acted as joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-302822","json":"https://secwatch.observer/filing/0001193125-22-302822.json","markdown":"https://secwatch.observer/filing/0001193125-22-302822.md","text":"https://secwatch.observer/filing/0001193125-22-302822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/0001193125-22-302822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/d397326d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:15:12.502652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcbfd3231b175e71e47f260d1b304af58a61c42c","claim":"Cabaletta Bio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Evercore Group L.L.C. (effective 2022-12-07).","evidence_excerpt":"On December 7, 2022, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Evercore Group L.L.C. (collectively, the “Underwriters”), relating to an underwritten offering","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/0001193125-22-302822-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cowen and Company, LLC and Evercore Group L.L.C."},{"label":"Effective","value":"2022-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}